ALNY
Alnylam Pharmaceuticals Inc
223.90$
+1.8%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 69.1% | 79.7% | 78.3% | 89.4% | 76.8% | 71.6% | 76.7% | 77.1% | 75.9% | 77.9% | 77.7% | 81.6% | |
| 7.0% | 13.0% | 15.3% | 32.4% | 26.7% | 22.8% | 14.6% | 22.5% | 24.4% | 21.2% | 22.8% | 33.4% | |
| 64.5% | 77.9% | 74.6% | 85.5% | 68.8% | 64.1% | 55.0% | 66.9% | 61.8% | 63.7% | 63.5% | 58.6% | |
| 3.7% | 0.6% | 1.8% | 1.7% | 1.2% | 1.8% | 17.7% | 5.5% | 6.7% | 8.6% | 9.6% | 15.7% | |
| 0.0% | 0.0% | 0.0% | 0.0% | 1.5% | 2.4% | 2.2% | 2.4% | 3.6% | 2.3% | 1.9% | 1.7% | |
| 2.0% | 2.0% | 9.1% | 9.1% | 20.4% | 17.8% | 13.6% | 13.8% | 14.8% | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | 7.5% | 18.2% | – | 12.0% | |
| 13.3% | 8.8% | 27.1% | 11.4% | 17.3% | 39.9% | 70.2% | 83.9% | 104.5% | 105.8% | 98.4% | 84.1% | |
| 8.8% | 4.5% | 15.3% | 9.9% | 15.4% | 14.7% | 17.2% | 19.1% | 21.7% | 25.3% | 28.0% | 29.5% | |
| 0.5% | 0.5% | 0.9% | 0.6% | 4.0% | 1.2% | 1.1% | 1.1% | 1.2% | 1.1% | 1.0% | 0.9% | |
| 1.4% | 1.2% | 4.3% | 1.4% | 3.8% | 2.1% | 1.5% | 2.0% | 2.8% | 1.4% | 2.1% | 2.3% | |
| 0.0% | 0.0% | 11.9% | 1.5% | 1.9% | – | 5.6% | 18.5% | 28.7% | 26.7% | 24.2% | 20.3% | |
| 86.7% | 91.2% | 72.9% | 88.6% | 82.7% | 60.1% | 29.8% | 16.1% | -4.5% | -5.8% | 1.6% | 15.9% | |
| -88.6% | -89.9% | -131.2% | -107.7% | -180.4% | -155.6% | -134.6% | -149.3% | -185.2% | -183.0% | -171.9% | -135.0% | |
| 6.9% | 6.1% | 6.8% | 4.5% | 6.4% | 4.6% | 3.4% | 3.3% | 3.4% | 3.3% | 3.0% | 2.7% |
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.